Literature DB >> 1961633

Graves exophthalmos unrelated to extraocular muscle enlargement. Superior rectus muscle inflammation may induce venous obstruction.

H L Hudson1, L Levin, S E Feldon.   

Abstract

Exophthalmos is the most commonly measured sign of Graves ophthalmopathy, whereas enlargement of the extraocular muscles is the principal pathologic abnormality. The purpose of this article is to explore possible etiologies of increased volume of orbital fat and of proptosis in patients with no substantially increased total extraocular muscle volume. Computed tomographic scans of the 13 orbits reviewed in this study had the following characteristics in common: a fine, reticular pattern within the orbital fat, a prominent superior ophthalmic vein, and an enlarged superior rectus muscle. Quantitative analysis revealed that superior rectus muscle volume showed a statistically significant correlation with proptosis, whereas medial, lateral, and inferior rectus muscle volumes did not correlate with proptosis. Based on anatomic considerations, the authors postulate that superior rectus muscle enlargement alone may produce reduced venous outflow from the orbit, thereby expanding the apparent orbital fat volume and producing proptosis.

Entities:  

Mesh:

Year:  1991        PMID: 1961633     DOI: 10.1016/s0161-6420(91)32099-2

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  12 in total

1.  Extraocular muscle changes in experimental orbital venous stasis: some similarities to Graves' orbitopathy.

Authors:  E Saber; J McDonnell; K M Zimmermann; J E Yugar; S E Feldon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-05       Impact factor: 3.117

Review 2.  Thyroid eye disease.

Authors:  D H Char
Journal:  Br J Ophthalmol       Date:  1996-10       Impact factor: 4.638

3.  Retrobulbar pressures measured during surgical decompression of the orbit.

Authors:  A J Otto; L Koornneef; M P Mourits; L Deen-van Leeuwen
Journal:  Br J Ophthalmol       Date:  1996-12       Impact factor: 4.638

4.  Orbital decompression surgery and horse chestnut seed extract improved superior orbital vein blood flow in patients with thyroid-associated ophthalmopathy.

Authors:  Yu-Jie Wu; Xin Wei; Man-Yi Xiao; Wei Xiong
Journal:  Int J Ophthalmol       Date:  2016-06-18       Impact factor: 1.779

5.  Colour Doppler imaging of the orbital vasculature in Graves' disease with computed tomographic correlation.

Authors:  M N Alp; A Ozgen; I Can; P Cakar; I Gunalp
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

6.  Color Doppler imaging of the superior ophthalmic vein in patients with Graves' orbitopathy before and after treatment of congestive disease.

Authors:  Mário L R Monteiro; Rodrigo B S Moritz; Hélio Angotti Neto; Joseph E Benabou
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

Review 7.  Thinking inside the box: Current insights into targeting orbital tissue remodeling and inflammation in thyroid eye disease.

Authors:  Vardaan Gupta; Christine L Hammond; Elisa Roztocil; Mithra O Gonzalez; Steven E Feldon; Collynn F Woeller
Journal:  Surv Ophthalmol       Date:  2021-09-04       Impact factor: 6.197

8.  Color Doppler imaging of the superior ophthalmic vein in different clinical forms of Graves' orbitopathy.

Authors:  Mário L R Monteiro; Hélio Angotti-Neto; Joseph E Benabou; Alberto J Betinjane
Journal:  Jpn J Ophthalmol       Date:  2008-12-17       Impact factor: 2.447

9.  Clinical and Radiological Findings in Patients with Newly Diagnosed Graves' Ophthalmopathy.

Authors:  Yakup Cevik; Hande Taylan Sekeroglu; Burce Ozgen; Kadriye Erkan Turan; Ali Sefik Sanac
Journal:  Int J Endocrinol       Date:  2021-04-30       Impact factor: 3.257

10.  Predicting dysthyroid optic neuropathy using computed tomography volumetric analyses of orbital structures.

Authors:  Allan C Pieroni Gonçalves; Lucas Nunes Silva; Eloísa M M S Gebrim; Suzana Matayoshi; Mário Luiz Ribeiro Monteiro
Journal:  Clinics (Sao Paulo)       Date:  2012-08       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.